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Abstract 
 
The aim of this multi-center, prospective, observer-blinded, parallel group, randomized 
controlled trial was to assess the safety and efficacy of EDX110, a nitric oxide generating 
medical device, in the treatment of diabetic foot ulcers in a patient group reflecting “real 
world” clinical practice compared against optimal standard care. Participants were recruited 
from ten hospital sites in multidisciplinary foot ulcer clinics. The ulcers were full thickness, 
with an area of 25-2500mm2 and either a palpable pedal pulse or ankle brachial pressure 
index >0.5. Infected ulcers were included. Treatment lasted 12 weeks, or until healed, with a 
12-week follow-up period. Both arms were given optimal debridement, offloading and 
antimicrobial treatment, the only difference being the fixed used of EDX110 as the wound 
dressing in the EDX110 group. 135 participants were recruited with 148 ulcers (EDX110 - 
75; Control - 73), 30% of which were clinically infected at baseline. EDX110 achieved its 
primary endpoint by attaining a median Percentage Area Reduction of 88.6% compared to 
46.9% for the control group (p=0.016) at 12 weeks in the Intent to Treat population. There 
was no significant difference between wound size reduction achieved by EDX110 after 4 
weeks and the wound size reduction achieved in the control group after 12 weeks. EDX110 
was well tolerated. Thirty serious adverse events were reported (12 in the EDX110 group, of 
which 4 were related to the ulcer; 18 in the control group, of which 10 were related and 1 
possibly related to the ulcer), with significant reduction in serious adverse events related to 
the ulcer in EDX group. There was no significant difference in adverse events. This study, in 
a real world clinical foot ulcer population, demonstrates the ability of EDX110 to improve 
healing, as measured by significantly reducing the ulcer area, compared to current best 
clinical practice. 
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Introduction 
 
Patients with diabetes have a lifetime incidence of up to 25% for developing diabetic foot 
ulcers (DFUs).1 These notoriously hard-to-heal ulcers are associated with poor clinical 
outcomes and a long-term impact on morbidity, mortality, and quality of life. DFUs account 
for almost 50% of diabetes-specific hospital admissions and precede more than 80% of 
amputations in people with diabetes, 2,3 the rate of which is 20 times that of people without 
diabetes. The latest figures show that, for 2014-15, the annual cost to the National Health 
Service in England for DFUs was between US$1.31bn m and $1.53bn.4 
 
Prior to this study, the lack of an evidence base for advanced wound dressings to manage 
DFUs was widely acknowledged.5,6 Each of the available guidelines for the treatment of DFU 
recommends debridement, pressure offloading, and an ‘appropriate’ dressing,5,7 and it is 
commonly stated there is little difference in efficacy between the many dressings in current 
use and a lack of robust data.3,5-8 Of note, some RCTs, although useful in establishing 
efficacy under ideal circumstances for a variety of wound-healing interventions, do not 
provide the necessary information to establish effectiveness in the “usual” compromised 
wound center patient.9 
The critical factors determining non-healing status of DFUs are ischemia and/or infection.10 
Nitric oxide (NO) plays a crucial role in maintaining the microvascular supply and infection 
control in the skin, and its absence in diabetes is a compounding factor in poor ulcer 
healing.11,12 The role of NO in ulcer healing involves three recognized elements: vascular, as 
NO influences blood vessel vasodilatation and stimulates angiogenesis;13,14 inflammatory, as 
NO influences the host immune response;15 and antimicrobial as NO demonstrates potent, 
broad spectrum antimicrobial activity.16 EDX110 (Edixomed, London, UK) is a two-layer 
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system designed to generate NO in-situ. EDX110 provides a moist wound environment, 
absorbs exudate, triggers autolytic debridement and, when the two layers are placed in 
contact and applied to the wound, nitric oxide (NO) is generated as an ancillary function.  
In addition, the antimicrobial action of EDX110 has been assessed in the laboratory via the 
AATCC Test Method 100, required by the FDA to claim antimicrobial activity, where it 
demonstrated microbicidal action against strains of gram-positive and gram-negative 
bacteria, mold and yeast.17 EDX110 has also demonstrated significant activity against 
biofilms.18 EDX110 prevented biofilms from forming and was bactericidal to established 
biofilms, including gram positive and gram negative bacteria, to multi-drug resistant strains 
and polymicrobial biofilms. 
The aim of this study, ProNOx1, was to assess the safety and efficacy of EDX110, a Class III 
medical device, compared to standard of care (SOC) dressings - the control group -  in the 
treatment of diabetic foot ulcers with a wide inclusion criteria to reflect the population in 
which EDX110 would inevitably be used if the study was successful. 
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Methods 
 
Study design  
The ProNOx1 study was a multi-center, prospective, observer-blinded, parallel group, 
randomized controlled trial of a NO-generating wound treatment versus current standard of 
care dressings in DFUs. Patients were recruited at ten established expert multidisciplinary 
clinics for the management of diabetic foot ulcers. 
 
The study was approved by the National Research Ethics Committee and the Medicines and 
Healthcare Products Regulatory Agency in the UK.  
 
Participants were aged 18 or over, with type 1 or type 2 diabetes and a chronic, (present for at 
least 6 weeks) full-thickness foot ulcer (on or below the malleoli) not penetrating to tendon, 
periosteum or bone, and with a cross-sectional area between 25 and 2500 mm2. Participants 
were required to have either a palpable pedal pulse, or an ankle-brachial pressure index 
(ABPI) of >0.5. Notably, participants with ulcer infection were not excluded.  
 
There was one relevant in-study substantial protocol amendment: inclusion was amended to 
allow entry to participants with ulcers >14 days duration reduced from 6 weeks to improve 
recruitment in February 2014. Duration of >14 days was chosen as a reasonable indicator of 
the chronicity of ulceration (8 ulcers of less than 4 weeks duration were included in the 
EDX110 group and 6 in the control group). 
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Procedures 
All participants received the normal DFU management procedures for each study site, with 
debridement, infection management including antibiotics when indicated, and offloading as 
clinically appropriate across both study arms. Following randomization, dressings were first 
applied to both study groups at the clinical centers. Participants were shown how to change 
and apply new dressings and subsequently, for both groups, dressing changes were primarily 
undertaken in the home. 
 
The EDX110 group used the EDX110 2-layer, NO-generating wound treatment. The primary 
layer of EDX110 is a moist mesh which is placed centrally over the ulcer. The secondary 
layer is then applied on top of the mesh, positioned so there is a similar sized border 
surrounding the primary layer, which retains the primary layer in place, see Figure 1. 
Participants were directed to change EDX110 every 48 hours. 
 
The investigators were instructed to treat the control group with whichever available dressing 
they considered best clinical practice for their participants at that time. These participants 
were directed to change the dressing as specifically indicated for the dressing being used. The 
investigators could alter the dressing type as clinically required, including using antimicrobial 
dressings as appropriate.  
 
The duration of treatment was 12 weeks, with clinical visits weekly for the first four weeks, 
and every 2 weeks thereafter. Between study visits, dressings were changed either by 
participants, their carers or by community healthcare professionals. A follow-up visit 
occurred for participants either at 12 weeks post-healing, or at week 24, whichever came first. 
Ulcer recurrence was recorded if a “new” ulcer was present at the same site as the original. 
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At each clinical visit, images of the ulcers were recorded using the Silhouette® system (Aranz 
Medical, Christchurch, New Zealand). The Silhouette® system is a proven wound imaging, 
3D measurement, and documentation system for clinical practice and clinical research 
allowing accurate quantitative data collection.19 
With the Silhouette® system it is possible to:  
1. calculate accurate wound surface area, depth, perimeter and volume 
2. combine imaging and measurement with assessment information to generate 
comprehensive reports 
3. immediately store wound information in a secure environment  
Critically, point 3 enabled every image of the study ulcers to be assessed and measured 
remotely by one wound care expert. This enabled completely blind assessment of the ulcer 
progression and removed any subjectivity providing a completely unbiased measure of the 
outcome.   
 
Outcomes 
The co-primary outcomes were the efficacy of EDX110 as assessed by the percentage ulcer 
area reduction from baseline (PAR) compared with the control group and the safety and 
tolerability of EDX110. PAR at 12 weeks was the primary efficacy measure. The percentage 
of ulcers healed at 12 weeks and ulcer recurrence were secondary outcomes.  
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PAR was measured by the blinded assessor using the Silhouette® system.19 Final healing 
status was determined by the center investigators, with healing defined as complete 
epithelialization of the ulcer, without drainage, and the blinded assessor confirmed complete 
epithelialization using the Silhouette® system. There were eight missing healed ulcer images 
where only the PI reported the healed ulcer. Infection was diagnosed by the investigator 
based on the presence of two classical signs of infection, including purulent discharge, 
erythema, pain, and swelling, as per standard clinical practice.20 
 
Serious adverse events (SAEs) and adverse events (AEs) were defined in the study protocol 
and complied with good clinical practice. Each event was classified by the local principal 
investigator for relatedness to the index ulcer and/or dressing.    
 
For the EDX110 group only, tolerability (at change of EDX110 and with EDX110 in situ) 
was recorded at each visit. At change, a validated Verbal Rating Score (VRS) was used, 
ranging from 1 to 6, where 1 = comfortable/pleasant and 6 = severe discomfort. For 
tolerability in situ, a Visual Analogue Scale (VAS) ranging from 1 to 10, where 1 = no 
sensation and 10 = severe discomfort, was utilized.  
 
Statistical Analysis 
Following power calculations with an 80% power to detect a 25-30% difference in healing 
between the 2 randomly assigned groups with 1:1 distribution, with a 20% attrition rate, 
based on a current standard of care healing rate of 25%,8,21 a study size of 60 participants in 
each arm was chosen. The test statistic used was the two-sided z test with pooled variance 
and a target significance level of 0.05. PAR was the intended primary efficacy measure as it 
can be measured by a blinded observer. It would have been preferable to use PAR for the 
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power calculation. However, the most robust data available for standard of care from 
Jeffcoate et al in 2009,8 only reported complete healing and this was used for the power 
calculation. 
 
The study was open-label, and treatment allocation followed a computer generated, center-
stratified randomization list in blocks of four – the centers were unaware of the 
randomization strategy. Participants were randomized 1:1 to the EDX110 group or the 
control group and assigned to their respective groups by the principal investigator at each 
center. The Silhouette® Wound Imaging System was used to capture images of the ulcer, 
from which an observer blinded assessment was conducted of all images by an independent 
wound care expert.  
 
For the efficacy endpoint, unadjusted analysis of PAR differences between the groups was 
conducted using Mann-Whitney U tests to account for non-normal distribution of PAR. The 
rates of complete healing were compared using Chi-squared tests. A post-hoc linear mixed 
effect model was also used to investigate the effects of different variables as random factors 
including clustering at the participant level, clustering at the site level, and ulcer area, ulcer 
age and infection status at randomization as fixed effects. The dependent variable was PAR at 
12 weeks and 4 weeks. Separate models were conducted for outcomes at 4 and 12 weeks. 
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Data were analyzed by intention-to-treat (ITT) population, and per-protocol (PP) population. 
Safety included analysis of all adverse outcomes in all participants and ulcers. The ITT 
population comprised all ulcers which received at least one treatment. Participants were 
excluded from the PP population if they withdrew consent or were withdrawn by the 
principal investigator or were withdrawn due to an unrelated AE/SAE, or experienced a 
serious protocol deviation unless they completed at least 10 weeks of treatment. Any 
participant with a healed ulcer or withdrawn for an ulcer-related AE/SAE remained in the PP 
population as these were critical outcomes. 
 
An independent statistical group conducted analysis. Hypothesis testing was performed for 
selected primary and secondary endpoints. Unless specified, all statistical testing was two-
sided and performed using a significance (alpha) level of 0.05. For continuous variables with 
approximately normal distribution, means and standard deviations (SD) were the preferred 
reporting metric while for non-normal variables, medians and interquartile ranges (IQR) were 
the preferred reporting metric, particularly PAR due to its non-normal distribution, but means 
and SDs are also included for completeness in the case of ulcer age, ulcer area and PAR. 
Missing data were imputed for the ITT population using the last observation carried forward 
principle.  
 
An explorative analysis compared the full ITT results to a cohort where only the first 
randomized ulcer was included for analysis if a participant’s second or subsequent 
randomized ulcer was being treated within the same cohort. 
 
An adjustment for multiplicity of statistical testing was made using a complex gatekeeping 
strategy for the ITT analysis and the step-up Hochberg procedure for the PP analysis for all 
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reported p values, with the reported p values being the adjusted values, except where 
otherwise explicitly stated.22 
 
For the safety and tolerability endpoints, AEs and SAEs were analyzed using a Chi-squared 
test.  
 
Results 
Study Demographics 
From October 2013, to July 2015, 217 ulcers were screened of which 147 were randomized 
(Figure 2). Seventy participants were excluded for either not meeting the ulcer inclusion 
criteria (n=45) or declining to participate (n=15), or other reasons (n=10).  
Three participants received no treatment post randomization, having withdrawn between 
consent and baseline and were removed from the ITT population.  
 
There were 135 participants receiving treatment in the study and 123 of these were 
randomized with one ulcer only. Three participants also had an ulcer on their contralateral 
foot and were re-entered into the study at a later date. One participant had two ulcers on the 
same foot treated with separate dressings. In four participants with simultaneous ulcers on 
both feet, the ulcer on the right was first randomized and then the ulcer on the left was 
automatically assigned to the other study group. In all the above cases, separate identification 
codes and CRFs were assigned to each DFU. 
 
In addition, four participants were included with two ulcers treated under the same dressing 
labelled as ulcer A and B in the same CRF. In one of these cases the participant was re-
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entered into the study at a later date with an ulcer on the contralateral foot, resulting in this 
participant having three ulcers in the study being documented in two separate CRFs. 
In all, 63 participants with 71 ulcers were treated with EDX110 only, 68 participants with 69 
ulcers were treated only with standard of care dressings and 4 participants had 8 bilateral 
ulcers, one of which was treated with EDX110 and the other treated with standard of care 
dressings.  
In summary, 123 participants had one ulcer, 11/135 participants each had two ulcers in the 
study, 1/135 participants had three ulcers in the study. There was a total of 144 CRFs 
(EDX110-72; control-72) reporting 148 ulcers (EDX110-75; control-73) in the study. As all 
148 ulcers received at least one treatment during the study, they were all included in the ITT 
population and safety analyses. 
The PP population comprised 114 participants with a total of 124 ulcers - 61 EDX110; 63 
control (Figure 2). 
 
There were no significant differences between the study groups with each having an expected 
higher proportion of male to female participants (Table 1). In the EDX110 group, 89% of 
ulcers and in the control group, 92% of ulcers had been present for at least one month. Thirty- 
eight different participant comorbidities were recorded, with no significant differences 
between the groups although of note, there were 17 (23%) prior amputations in the EDX110 
group, (6 major, 11 minor) and 10 (14%) in the control group, (4 major, 6 minor). 
 
Efficacy Analysis 
There was a significant improvement in the median PAR at 12 weeks in the EDX110 group 
compared to control in both the ITT (p=0.016) and PP (p=0.012) populations (Table 2). The 
progression of median PAR is shown in Figure 3, indicating no significant difference in the 
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PAR achieved by EDX110 in 4 weeks compared to that achieved by control in 12 weeks. 
There was also a significant improvement (p=0.036) in the median PAR at 4 weeks in the 
EDX110 compared to control in the PP population (Table 2). A post-hoc linear mixed model 
analysis of the full, 148 wound ITT population at 4 weeks indicated a significant difference 
in mean PAR between groups of 17.3 in favor of EDX110 (p=0.031) and, importantly, 
showed that no other fixed effect variables or random effect variables generated a significant 
difference in outcome in the model. 
 
In the ITT analysis, the proportion of ulcers healed at 12 weeks with EDX110 was 30/75 
(40%) and in the Control group was 19/73 (26%) (p=0.07). However, following a strict 
definition of ITT, including the 3 patients randomized but not treated, to give a control 
population of 76, the difference in complete healing is significant, p=0.049. The complete 
healed rate at 12 weeks in the PP analysis was significant, with 49% for the EDX110 group 
(30/61) compared to 30% for the control group (19/63) (p=0.04).  
 
The percentage of DFUs demonstrating 50% ulcer area reduction at 4 weeks in the ITT 
population, an important measure for clinicians,23,24 showed a significant difference in favor 
of EDX110 (53% vs 36%; p=0.03).  
 
The median PAR at 12 weeks for DFUs present for 6 months, was significantly greater for 
EDX110 (n=51; PAR=97%) compared with the control group (n=44; PAR=55%) (p=0.04). 
For those ulcers present for greater than 6 months there was no significant difference between 
the groups. (Table 2) 
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The median PAR at 12 weeks for DFUs that were ≥1cm2 at baseline, was significantly 
greater for EDX110 (n=32; PAR=82%) compared with the control group (n=32; PAR=29%) 
(p=0.007). For those ulcers <1cm2 at baseline, there was no significant difference between 
the groups. (Table 2) 
 
The percentage of healed ulcers in the EDX110 group for those ulcers classified as infected at 
baseline was 45% (9/20) compared to 23% (5/22) in the control group (p=0.20). In those 
ulcers classified as non-infected at baseline, EDX110 achieved complete healing of 38% 
(21/55) vs 27% (14/51) in the control group (p=0.24).  
 
The explorative analysis, including only a participant’s first randomized ulcer if their second 
or subsequent ulcer was treated with the same dressing, showed negligible difference from 
the ITT population. The mean PAR for EDX110 and control group remained the same as the 
ITT population at 59% and 37% respectively. The complete healing rate also remained the 
same as for the full ITT ulcer population, EDX110 - 40% vs control group - 26%. 
 
Ulcer recurrence at 12 weeks post healing was 1/23 (4%) in EDX110 and 4/16 (25%) in the 
control group, which did not reach statistical significance. 
 
Safety Analysis 
Thirty SAEs were recorded (EDX110 - 12 SAEs in 12 participants; control group - 18 SAEs 
in 15 participants) of which 14 were considered related and one possibly related to the study 
ulcer, (EDX110 - 4; control group - 11) but no SAE was reported as related to EDX110 or the 
SOC dressings. The fewer occurrences of SAEs related or possibly related to the ulcer in the 
EDX group compared with the SOC group was significant (p=0.049). There was no 
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significant difference in the overall number of SAEs between the EDX110 and control 
groups. The SAEs included two major amputations, and one death in hospital from 
septicemia and pneumonia following osteomyelitis of the index ulcer, all in the SOC group.  
 
There was no significant difference in AE occurrence between the study groups (EDX110 - 
49 AEs in 32 participants; control group - 54 AEs in 34 participants). The most common AE 
was foot infection: EDX110 – 17 (35%); control group: 19 (35%). Amongst the foot 
infections in the EDX110 group reported as AEs, 12 were related to the index ulcer, four 
(33%) of which became serious adverse events. In the control group, 14 foot infections 
reported as AEs were related to the index ulcer, 9 (64%) of which became serious adverse 
events. 
 
EDX110 was well tolerated with a mean score of 1.7 (SD: 0.73) on a VRS at dressing change 
and 1.6 (SD: 1.01) on a VAS when in situ.  
 
The median number of dressing changes for the EDX110 group per week was 3.5; (IQR: 
1.8), as per instructions. The median number of dressing changes for the control group per 
week was 1.6; (IQR: 1.3).  
 
Nine different types of dressing were recorded in the control group - absorbent pad, alginate, 
anti-microbial, foam, gauze, gel fiber, hydro-colloid, hydrofiber or hydrogel and 32% of the 
dressings used were classified as anti-microbial, namely iodine, honey, polyhexamethylene 
biguanide (PHMB) or hydrophobic (Sorbact®).  
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No clinically meaningful difference was seen in offloading between the 2 arms; 58% of 
patients received offloading in each group and this corresponds with the plantar location of 
63% of ulcers in the EDX group and 60% in the control group. 
 
Discussion 
This multicenter, prospective, observer blinded, randomized controlled trial has shown that 
treatment of diabetic foot ulcers with EDX110 was safe and well tolerated. Furthermore, the 
PAR at 12 weeks was significantly improved in the EDX110 group compared with the 
control group. The percentage of DFUs demonstrating >50% PAR at 4 weeks additionally 
showed a significant difference in favor of EDX110. The rate of complete healing improved 
significantly in 12 weeks with EDX110 in the PP population and also in the ITT population, 
if the strictest definition of ITT had been followed. The ulcers treated with EDX110 were 
associated with a significantly smaller number of SAEs which were related or possibly 
related to the study ulcer compared to those treated with SOC dressings. (p=0.049)  
Thus, there may be a significant clinical benefit gained by using EDX110 in a therapy area 
where recent overviews concluded that currently there is no robust evidence that any 
advanced dressing type is more effective than basic wound contact dressings.5,6,25  
 
In the Eurodiale prospective study on determinants of outcome in diabetic foot disease, the 
combination of infection with ischemia had a major negative impact on healing rates of 
DFUs.10 In this present real-life study, which allowed entry to participants with clinically 
infected ulcers and/or an ABPI as low as 0.5, the greater reduction in ulcer area may be 
attributed to the ability of EDX110 to generate a sustained release of NO that overcomes the 
issue of infection and ischemia. In many chronic ulcers, and especially in patients with 
diabetes, the generation of NO is lost or impaired.26 Previous development of a functional 
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NO wound treatment has been complicated by the very short half-life of the gas. EDX110 has 
overcome this issue with a sustained release of NO. This prolonged action of NO may be a 
major factor in the improved healing rate and makes EDX110 applicable to any chronic ulcer 
situation where ischemia and infection are factors in delayed healing. In the infected ulcers 
treated with EDX110, there was a doubling of complete healing compared to those treated 
with standard of care dressings. However, the number of infected ulcers was small and the 
number that healed approached, but did not reach, significance. Nevertheless, there are strong 
in vitro data to support the antimicrobial activity of NO as the skin’s ‘natural antibiotic’,16 
and EDX110 appears to be a useful treatment for infected ulcers. 
 
The beneficial effect of EDX110 was particularly useful in the subgroup of ulcers ≥1cm2 at 
baseline and in the subgroup of ulcers of ≤6 months duration relative to the control group. 
Furthermore, within the EDX110 group itself, there was also a significant improvement in 
PAR of ulcers of ≤6 months duration compared to that of ulcers of >6 months duration. This 
was not seen in the control group. Modern diabetic foot care encourages early presentation to 
specialist care, in keeping with advice and findings from the UK National Diabetic Foot 
Audit.27 Such a policy would facilitate the optimum healing effect of EDX110 when applied 
to ulcers of short duration.  
 
This study may be seen to have certain limitations. Reduction in ulcer size was used as the 
primary outcome as opposed to the commonly utilized outcome of complete healing. 
Reduction in ulcer size was used for two scientifically legitimate reasons. Firstly, complete 
healing measured by the investigator is both subjective and non-blind, opening the outcome 
to bias. The use of an accurate, quantitative and reproducible measuring system allowed a 
non-subjective, non-biased measure of percentage reduction in ulcer size to be the primary 
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outcome. Secondly, PAR is a clinically relevant outcome as it reflects the “healing” effect of 
standard of care dressings or EDX110 on the whole group and accounts for ulcers that are 
improving, static or, importantly, increasing in size, as well as those that heal. Therefore, an 
observer blinded outcome was the strongest alternative to remove bias and subjectivity. Also, 
the ProNOx1 study included all-comers and therefore contained a small number of 
participants with multiple ulcers which may be perceived as a limitation in that the inclusion 
of these participants may detract from the purity of the statistical analysis. However, a mixed 
model analysis, assessing the impact of variables, including the presence of multiple ulcers, 
showed that the only factor that significantly affected outcome was treatment arm and a 
direct comparison of the results showed that the inclusion of multiple ulcers had negligible 
effect.   
 
A further possible limitation of the study was the choice of a non-standardized dressing 
protocol in the control group with inevitable lack of blinding.  There is no evidence that any 
specific dressing is superior in clinical practice and thus, investigators were allowed their 
optimal choice dependent on the ulcer condition at each visit. This was arguably a much 
tougher comparator for EDX110. True blinding would have required the use of a placebo 
dressing, which would not have offered optimal treatment to the control group. At best this 
would have been judged an unfair advantage for EDX110, at worst it would be unethical 
treatment of the participants. A further limitation with respect to dressings was that the mean 
number of dressing changes was greater in the EDX110 group. Whilst this might be 
perceived as an advantage for EDX110, there is no evidence to suggest more frequent 
dressing changes improve healing, or it would be standard practice to change all dressings 
more frequently.  
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In the last decade, there has been growing concern that the results from many RCTs cannot 
be generalized to the wound care population.9 However, in the present trial, a “real world” 
wound care population was studied, including participants with moderate ischemia and ulcers 
complicated by infection, and EDX110 still met its primary endpoint and showed substantial 
promise. It was well tolerated, with significantly smaller numbers of SAEs which were 
related or possibly related to the study ulcer compared to those treated with SOC dressings. It 
also significantly improved the reduction of ulcer area compared with SOC dressings, notably 
in those with a duration of less than six months. 
 
The trial was registered at ClinicalTrials.gov, number NCT01982565.  
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Table 1: Baseline demographics of the intention-to-treat population 
 
Parameter EDX110 Control 
Age (years)
*
 59.3 (SD 12.41) 59.0 (SD 11.85) 
   Male
*
 
   Female
*
 
63 (87%) 
9 (13%) 
59 (82%) 
13 (18%) 
Palpable foot pulse
* 
   
   Yes 68 (94%) 62 (87%) 
   No 4 (6%) 9 (13%) 
Blood pressure (mmHg)
†
   
   Systolic 143.9 (21.11) 143.3 (21.89) 
   Diastolic 81.9 (13.13) 81.2 (15.45) 
Blood glucose (mmol/L)
*
 9.9 (5.68) 10.2 (4.11) 
ABPI
*
 1.26 (0.55) 1.24 (0.28) 
Bypass graft  3 (4) 7 (10) 
DFU age (weeks)
‡ 
  
   Mean 28.9 (35.1) 41.1 (54.7) 
   Median 13.0 (33.1) 19.6 (44.1) 
DFU age (weeks)
‡ 
  
   >26 24 (32%) 28 (39%) 
   26 51 (68%) 44 (61%) 
Initial area (cm
2
)
†
   
   Mean 2.10 (3.33) 1.58 (2.22) 
   Median 0.86 (1.89) 0.7 (1.26) 
Area (cm
2
)   
   <0.25 8 (11) 12 (16) 
   ≥0.25 67 (89) 61 (84) 
Area (cm
2
)
†
   
   <1.0 43 (57) 41 (56) 
   ≥1.0 32 (43) 32 (44) 
Plantar ulcer
†
 47 (63) 44 (60) 
Location
†
   
   Toe 15 (20) 14 (19) 
   Foot 50 (67) 46 (63) 
   Heel/ankle 10 (13) 13 (18) 
DFU offloaded 44 (58) 42 (58) 
DFU infected
§
 20 (30) 22 (34) 
 
Parameters are specified as mean (SD; standard deviation) and as median (interquartile range 
for non-normal data) and numbers (%) for categories. 
*
These data are presented for each case 
report form, n=144; there were 9 participants in the EDX110 group and 10 participants in the 
control group with ABPI data.
‡
 Duration of ulcer data was missing for 1 control ulcer.
† 
These 
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data are presented for DFUs, n=148. 
§
Infection data available for 66 DFUs in the EDX110 
group and 64 DFUs in the control group  
There are no significant differences in baseline parameters. 
APBI = Ankle Pressure Brachial Index; DFU = diabetic foot ulcer;  
 
 
This article is protected by copyright. All rights reserved.
Table 2: Percentage ulcer area reductions in specific ulcer populations 
 
 
Mean (SD) Median (IQR) 
P EDX110 Control EDX110 Control 
PAR at 12-Weeks 
ITT n=75  
58.7 (59.20) 
n=73 
37.0 (80.58) 
n=75 
88.6 (73.7) 
n=73 
46.9 (100) 
0.016* 
PP n=61 
71.0 (50.39) 
n=63 
38.6 (85.66) 
n=61 
98.5 (36.9) 
n=63 
52.1 (98.5) 
0.012* 
PAR at 4-Weeks 
ITT n=75 
45.4 (45.96) 
n=73 
31.7 (47.73) 
n=75 
53.7 (60.5) 
n=73 
34.4 (61.1) 
0.097* 
PP n=61 
55.4 (37.89) 
n=63 
32.9 (49.82) 
n=61 
55.9 (53.7) 
n=63 
36.3 (58.7) 
0.036* 
PAR related to ulcer duration at baseline (ITT ulcer population)
†
 
6 
months 
n=51 
67.1 (56.8)
‡ 
n=44 
37.8 (93.0)
§ 
n=51 
97.0 (37.4) 
n=44 
55 (88.7) 
0.04 
>6 
months 
n=24 
40.8 (61.4)
‡ 
n=28 
42.8 (45.0)
§ 
n=24 
47 (87) 
n=28 
46 (84) 
0.80 
PAR related to ulcer area at baseline (ITT ulcer population) 
≥1cm2 
 
n=32 
59.4 (45.5) 
n=32 
29.3 (42.2) 
n=32 
82.0 (77.6) 
n=32 
29.2 (55.4) 
0.007 
<1cm
2
 n=43 
58.2 (68.1) 
n=41 
43.0 (101.1) 
n=43 
100 (70.4) 
n=41 
92.1 (87.7) 
0.52 
 
SD = Standard Deviation; IQR = Inter Quartile Range; ITT = intention-to-treat; PP = per-
protocol 
* p values were obtained by Mann-Whitney test adjusted for multiplicity of statistical testing 
(no * means not adjusted for multiplicity of testing) 
† Duration of ulcer data was missing for 1 Control ulcer. 
‡ There is a significant improvement in healing between those treated with EDX110 with 
ulcers of ≤ 6 months duration compared with those treated with EDX110 with ulcers of > 6 
months duration (p=0.015; Mann Whitney) 
§ There is no significant difference in healing of ulcers of ≤ 6 months duration treated in the 
control group compared with healing of those ulcers of > 6 months duration treated in the 
control group (p=0.42; Mann Whitney) 
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A sterile wound treatment as two 
components: 
1. A primary non-adherent mesh 
2. A protective layer which 
generates nitric oxide when 
placed on the primary layer 
Wound 
Secondary layer 
Primary layer 
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Enrollment Assessed for eligibility (n=217) 
Excluded (n=70) 
• Did not meet ulcer inclusion criteria 
(n=45)1 
• Declined to participate (n=15) 
• Other reason (n=10)2 
Randomised (n=147) 
Allocated to EDX110 (n=72) 
• Received allocated intervention (n=72) 
• Did not receive allocated intervention (n=0) 
Allocated to Control (n=75) 
• Received allocated intervention (n=72) 
• Did not receive allocated intervention (n=3)3 
Withdrawn (n=18): 
SAE related to ulcer (n=2), SAE unrelated to ulcer (n=1), 
AE unrelated to ulcer (n=1), Investigator decision (n=2), 
Withdrawn consent (n=3), Protocol deviation (n=5), Lost 
to follow-up (n=4) 
Withdrawn (n=15): 
SAE related to ulcer (n=5)4, SAE unrelated to ulcer (n=2), 
AE unrelated to ulcer (n=1), Investigator decision (n=0), 
Withdrawn consent (n=3), Protocol deviation (n=3), Lost 
to follow-up (n=1) 
Analysed (n=75) 
• Excluded from analysis (n=0) 
Analysed (n=73) 
• Excluded from analysis (n=0) 
Randomised  
Wounds 
Non-completion 
of study in ITT 
ITT Population 
2 wounds treated under the same dressing 
(n=3 participants) 
2 wounds treated under the same dressing 
(n=1 participant) 
Non-Randomised  
Wounds 
Excluded (n=14): 
SAE unrelated to ulcer (n=1), AE unrelated to ulcer (n=1), 
Investigator decision (n=2)5, Withdrawn consent (n=2), 
Protocol deviation (n=5), Lost to follow-up (n=3) 
Excluded (n=10): 
SAE unrelated to ulcer (n=2), AE unrelated to ulcer (n=1), 
Investigator decision (n=0), Withdrawn consent (n=3), 
Protocol deviation (n=3), Lost to follow-up (n=1) 
Analysed (n=61) 
• Excluded from analysis (n=14) 
Analysed (n=63) 
• Excluded from analysis (n=10) 
Exclusion from 
PP Population 
PP Population 
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ITT Population PP Population 
Control 
EDX110 
Control 
EDX110 
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